Module 3 Authorship & Review
HomeServicesCMC & Quality ComplianceModule 3 Authorship & Review
Back to CMC & Quality Compliance

Module 3 Authorship & Review

Translating Technical Data into Regulatory Success

Overview

Module 3 is often the most complex and scrutinized section of any regulatory submission. Our CMC experts don't just write; we craft a narrative that links your manufacturing process, control strategy, and stability data to patient safety. We ensure your Quality dossier is scientifically sound, compliant with ICH guidelines, and ready for approval.

Key Features

Drug Substance (3.2.S) & Drug Product (3.2.P) writing
QOS (Module 2.3) preparation
Justification of specifications
Change control integration

Our Process

1

Data Review

Auditing your raw data and reports for completeness and accuracy.

2

Narrative Construction

Building the story of your product's development and quality control.

3

Gap Remediation

Identifying and fixing missing links before the agency sees them.

Project Complete & Deliverables Provided

Frequently Asked Questions

Inadequate justification of specifications. The FDA wants to see how you arrived at your acceptance criteria—not just the number, but the rationale. If your impurity limit is 0.5%, you need data showing this is safe and achievable. We ensure every spec has a clear link to safety, efficacy, and manufacturing capability.

Why Choose Us

  • Fewer Information Requests during review
  • Robust defense of control strategies
  • Consistency across global submissions
  • Clear traceability of data

Get More Details

Request a personalized consultation and detailed information about this service.

Personalized consultation
Detailed service information
Custom timeline & proposal
Request Information

We'll respond within 24 hours

Ready to get started?

Contact our team to discuss your specific needs for Module 3 Authorship & Review.

Schedule Consultation

What Our Clients Say

"Our Module 3 was scrutinized heavily during review, but Adelphi's documentation was so thorough that we received zero CMC-related information requests. The reviewers even complimented our clarity."

Jennifer Liu

VP Quality

Mid-Size Biotech